HARMONY BIOSCIENCES HOLDINGS (HRMY) Fundamental Analysis & Valuation

NASDAQ:HRMY • US4131971040

Current stock price

28 USD
+0.39 (+1.41%)
Last:

This HRMY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. HRMY Profitability Analysis

1.1 Basic Checks

  • In the past year HRMY was profitable.
  • In the past year HRMY had a positive cash flow from operations.
  • Each year in the past 5 years HRMY has been profitable.
  • HRMY had a positive operating cash flow in each of the past 5 years.
HRMY Yearly Net Income VS EBIT VS OCF VS FCFHRMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 12.48%, HRMY belongs to the top of the industry, outperforming 93.23% of the companies in the same industry.
  • HRMY's Return On Equity of 18.24% is amongst the best of the industry. HRMY outperforms 90.63% of its industry peers.
  • With an excellent Return On Invested Capital value of 15.30%, HRMY belongs to the best of the industry, outperforming 94.27% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for HRMY is above the industry average of 13.57%.
Industry RankSector Rank
ROA 12.48%
ROE 18.24%
ROIC 15.3%
ROA(3y)14.31%
ROA(5y)15.57%
ROE(3y)22.63%
ROE(5y)26.3%
ROIC(3y)18.27%
ROIC(5y)17.43%
HRMY Yearly ROA, ROE, ROICHRMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K 1.5K

1.3 Margins

  • HRMY's Profit Margin of 18.27% is amongst the best of the industry. HRMY outperforms 91.67% of its industry peers.
  • HRMY's Profit Margin has declined in the last couple of years.
  • With an excellent Operating Margin value of 24.00%, HRMY belongs to the best of the industry, outperforming 91.15% of the companies in the same industry.
  • In the last couple of years the Operating Margin of HRMY has grown nicely.
  • HRMY has a Gross Margin of 77.16%. This is amongst the best in the industry. HRMY outperforms 83.85% of its industry peers.
  • In the last couple of years the Gross Margin of HRMY has remained more or less at the same level.
Industry RankSector Rank
OM 24%
PM (TTM) 18.27%
GM 77.16%
OM growth 3Y-4.37%
OM growth 5Y17.8%
PM growth 3Y-23.89%
PM growth 5YN/A
GM growth 3Y-1.58%
GM growth 5Y-1.37%
HRMY Yearly Profit, Operating, Gross MarginsHRMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. HRMY Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HRMY is creating value.
  • Compared to 1 year ago, HRMY has more shares outstanding
  • HRMY has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, HRMY has an improved debt to assets ratio.
HRMY Yearly Shares OutstandingHRMY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
HRMY Yearly Total Debt VS Total AssetsHRMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 4.41 indicates that HRMY is not in any danger for bankruptcy at the moment.
  • HRMY has a Altman-Z score of 4.41. This is in the better half of the industry: HRMY outperforms 74.48% of its industry peers.
  • HRMY has a debt to FCF ratio of 0.50. This is a very positive value and a sign of high solvency as it would only need 0.50 years to pay back of all of its debts.
  • HRMY has a Debt to FCF ratio of 0.50. This is amongst the best in the industry. HRMY outperforms 96.88% of its industry peers.
  • HRMY has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of HRMY (0.17) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF 0.5
Altman-Z 4.41
ROIC/WACC1.61
WACC9.5%
HRMY Yearly LT Debt VS Equity VS FCFHRMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

2.3 Liquidity

  • HRMY has a Current Ratio of 3.60. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
  • HRMY has a Current ratio of 3.60. This is comparable to the rest of the industry: HRMY outperforms 57.29% of its industry peers.
  • HRMY has a Quick Ratio of 3.58. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.58, HRMY perfoms like the industry average, outperforming 58.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.58
HRMY Yearly Current Assets VS Current LiabilitesHRMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. HRMY Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.97% over the past year.
  • HRMY shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -4.69% yearly.
  • The Revenue has grown by 21.51% in the past year. This is a very strong growth!
  • The Revenue has been growing by 40.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)7.97%
EPS 3Y-4.69%
EPS 5YN/A
EPS Q2Q%-55.29%
Revenue 1Y (TTM)21.51%
Revenue growth 3Y25.64%
Revenue growth 5Y40.31%
Sales Q2Q%21.12%

3.2 Future

  • HRMY is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.39% yearly.
  • Based on estimates for the next years, HRMY will show a small growth in Revenue. The Revenue will grow by 5.39% on average per year.
EPS Next Y33.68%
EPS Next 2Y26.09%
EPS Next 3Y23.17%
EPS Next 5Y6.39%
Revenue Next Year17.98%
Revenue Next 2Y15.2%
Revenue Next 3Y14.28%
Revenue Next 5Y5.39%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HRMY Yearly Revenue VS EstimatesHRMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
HRMY Yearly EPS VS EstimatesHRMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

9

4. HRMY Valuation Analysis

4.1 Price/Earnings Ratio

  • HRMY is valuated reasonably with a Price/Earnings ratio of 10.33.
  • 90.10% of the companies in the same industry are more expensive than HRMY, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 25.71. HRMY is valued rather cheaply when compared to this.
  • HRMY is valuated cheaply with a Price/Forward Earnings ratio of 7.73.
  • HRMY's Price/Forward Earnings ratio is rather cheap when compared to the industry. HRMY is cheaper than 91.67% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.83, HRMY is valued rather cheaply.
Industry RankSector Rank
PE 10.33
Fwd PE 7.73
HRMY Price Earnings VS Forward Price EarningsHRMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • HRMY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HRMY is cheaper than 97.40% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 95.83% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 4.93
EV/EBITDA 4.12
HRMY Per share dataHRMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • HRMY has an outstanding profitability rating, which may justify a higher PE ratio.
  • HRMY's earnings are expected to grow with 23.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y26.09%
EPS Next 3Y23.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HRMY Dividend Analysis

5.1 Amount

  • No dividends for HRMY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HRMY Fundamentals: All Metrics, Ratios and Statistics

HARMONY BIOSCIENCES HOLDINGS

NASDAQ:HRMY (3/16/2026, 3:03:51 PM)

28

+0.39 (+1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners89.56%
Inst Owner Change4.9%
Ins Owners1.62%
Ins Owner Change-0.04%
Market Cap1.62B
Revenue(TTM)868.45M
Net Income(TTM)158.69M
Analysts75.29
Price Target46.55 (66.25%)
Short Float %15.83%
Short Ratio8.77
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.41%
Min EPS beat(2)-58.44%
Max EPS beat(2)1.62%
EPS beat(4)2
Avg EPS beat(4)-9.25%
Min EPS beat(4)-58.44%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)51.32%
EPS beat(12)8
Avg EPS beat(12)36.66%
EPS beat(16)11
Avg EPS beat(16)92.62%
Revenue beat(2)1
Avg Revenue beat(2)2.19%
Min Revenue beat(2)-0.58%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.02%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-0.78%
Revenue beat(12)3
Avg Revenue beat(12)-0.81%
Revenue beat(16)5
Avg Revenue beat(16)-0.7%
PT rev (1m)-1.76%
PT rev (3m)-1.18%
EPS NQ rev (1m)-12.73%
EPS NQ rev (3m)-12.9%
EPS NY rev (1m)-16.18%
EPS NY rev (3m)-14.26%
Revenue NQ rev (1m)1.82%
Revenue NQ rev (3m)1.82%
Revenue NY rev (1m)1.56%
Revenue NY rev (3m)1.86%
Valuation
Industry RankSector Rank
PE 10.33
Fwd PE 7.73
P/S 1.86
P/FCF 4.93
P/OCF 4.65
P/B 1.86
P/tB 2.07
EV/EBITDA 4.12
EPS(TTM)2.71
EY9.68%
EPS(NY)3.62
Fwd EY12.94%
FCF(TTM)5.68
FCFY20.29%
OCF(TTM)6.02
OCFY21.5%
SpS15.01
BVpS15.05
TBVpS13.5
PEG (NY)0.31
PEG (5Y)N/A
Graham Number30.29
Profitability
Industry RankSector Rank
ROA 12.48%
ROE 18.24%
ROCE 20.45%
ROIC 15.3%
ROICexc 63.88%
ROICexgc 100.8%
OM 24%
PM (TTM) 18.27%
GM 77.16%
FCFM 37.84%
ROA(3y)14.31%
ROA(5y)15.57%
ROE(3y)22.63%
ROE(5y)26.3%
ROIC(3y)18.27%
ROIC(5y)17.43%
ROICexc(3y)50.91%
ROICexc(5y)46.17%
ROICexgc(3y)83.62%
ROICexgc(5y)1001.65%
ROCE(3y)24.42%
ROCE(5y)23.3%
ROICexgc growth 3Y7.52%
ROICexgc growth 5YN/A
ROICexc growth 3Y24.53%
ROICexc growth 5Y26.45%
OM growth 3Y-4.37%
OM growth 5Y17.8%
PM growth 3Y-23.89%
PM growth 5YN/A
GM growth 3Y-1.58%
GM growth 5Y-1.37%
F-Score5
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF 0.5
Debt/EBITDA 0.61
Cap/Depr 77.21%
Cap/Sales 2.25%
Interest Coverage 14.2
Cash Conversion 148.93%
Profit Quality 207.1%
Current Ratio 3.6
Quick Ratio 3.58
Altman-Z 4.41
F-Score5
WACC9.5%
ROIC/WACC1.61
Cap/Depr(3y)27.76%
Cap/Depr(5y)157.72%
Cap/Sales(3y)0.82%
Cap/Sales(5y)8.9%
Profit Quality(3y)175.8%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.97%
EPS 3Y-4.69%
EPS 5YN/A
EPS Q2Q%-55.29%
EPS Next Y33.68%
EPS Next 2Y26.09%
EPS Next 3Y23.17%
EPS Next 5Y6.39%
Revenue 1Y (TTM)21.51%
Revenue growth 3Y25.64%
Revenue growth 5Y40.31%
Sales Q2Q%21.12%
Revenue Next Year17.98%
Revenue Next 2Y15.2%
Revenue Next 3Y14.28%
Revenue Next 5Y5.39%
EBIT growth 1Y0.5%
EBIT growth 3Y20.15%
EBIT growth 5Y65.28%
EBIT Next Year34.86%
EBIT Next 3Y11.95%
EBIT Next 5Y7.8%
FCF growth 1Y50.29%
FCF growth 3Y46.6%
FCF growth 5YN/A
OCF growth 1Y58.4%
OCF growth 3Y34.07%
OCF growth 5YN/A

HARMONY BIOSCIENCES HOLDINGS / HRMY Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?

ChartMill assigns a fundamental rating of 7 / 10 to HRMY.


What is the valuation status of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?

ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.


Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?

HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.


What are the PE and PB ratios of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?

The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 10.33 and the Price/Book (PB) ratio is 1.86.


What is the earnings growth outlook for HARMONY BIOSCIENCES HOLDINGS?

The Earnings per Share (EPS) of HARMONY BIOSCIENCES HOLDINGS (HRMY) is expected to grow by 33.68% in the next year.